Tag: licensing
-
Carb-X Funds Drug-Resistant Bacterial Vaccine
A company developing vaccines with synthetic biology is receiving a grant for a vaccine to prevent infections from drug-resistant Klebsiella pneumoniae bacteria.
-
Company Forms to Treat Vaginal Microbial Disorders
A new enterprise has launched to develop live microbial treatments for urinary tract infections and other diseases originating in vaginal bacterial communities.
-
A.I. Helps Visualize Emergency Social Media Data
A set of computational tools developed at Purdue University enables public safety agencies to monitor potentially catastrophic events in real time by analyzing text and images on social media.
-
Hearing Loss Cell Therapy Licensed in $625M Deal
A biotechnology company developing regenerative treatments for various disorders is licensing its lead therapy candidate for hearing loss to Astellas Pharma.
-
Genentech, Biotech Partner on Multiple Sclerosis
A company designing treatments to restore the protective coating on nerve cells damaged by multiple sclerosis is collaborating with biotechnology enterprise Genentech.
-
Immunotherapy Biotech Gains $325M in Venture Funds
A biotechnology enterprise developing personalized treatments for cancer and infectious diseases is raising $325 million in its second venture funding round.
-
Start-Up Creating Blood Tests, Apps for Mental Disorders
A new enterprise based on psychiatric and molecular research at Indiana University is developing precision-medicine diagnostics for pain and mental disease.
-
Stem Cell Start-Up Raises $250M in Venture Funds
A company begun last year to create cancer therapies from banked, off-the-shelf stem cells is raising $250 million in its first round of venture financing.
-
Augmented Reality, A.I. Harnessed to Visualize Pain
Researchers at University of Michigan created a system with real-time neurological imaging, algorithms, and augmented reality to detect and visualize a patient’s pain.
-
Company Launches Attacking Cancer Proteins, Lands $67M
A new enterprise is starting-up to develop treatments that target cancer-causing proteins considered unreachable with current therapies.